shaken not stirred, page-6

Guys, one of the problems I see in all of this "over promising and under delivering" is that it does not give me as a shareholder confidence that, even if we get good HCV results and have interest from big pharma, the management team has the wherewithal to negotiate the best outcome for shareholders. I can see us getting short changed on a deal and that is something that we may just have to accept in the hope that the NSCLC will produce a fair market price.

At least a deal should get us enough cash to re-start our other programs and, if the HCV results are good, an interested party may want both the HCV and the HBV programs. That kind of deal, even if it is on the low side compare to other RNAi deals, should be enough to see the sp start to match its potential.

Alnylam and ISIS have been good at stitching up these sorts of deals and it is about time we were as good!